Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 68

1.

Lesson of the month 2: Cauda equina in Cushing's syndrome.

Maslin D, Gounaris I, Ng K, Corrie P.

Clin Med (Lond). 2016 Feb;16(1):88-90. doi: 10.7861/clinmedicine.16-1-88.

PMID:
26833526
2.

Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.

Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, Tomasek J, Raderer M, Lahner H, Voi M, Pacaud LB, Rouyrre N, Sachs C, Valle JW, Delle Fave G, Van Cutsem E, Tesselaar M, Shimada Y, Oh DY, Strosberg J, Kulke MH, Pavel ME; RAD001 in Advanced Neuroendocrine Tumours, Fourth Trial (RADIANT-4) Study Group.

Lancet. 2016 Mar 5;387(10022):968-77. doi: 10.1016/S0140-6736(15)00817-X. Epub 2015 Dec 17.

PMID:
26703889
3.

Withdrawal of anticancer therapy in advanced disease: a systematic literature review.

Clarke G, Johnston S, Corrie P, Kuhn I, Barclay S.

BMC Cancer. 2015 Nov 11;15:892. doi: 10.1186/s12885-015-1862-0. Review.

4.

Evolving treatment options for melanoma brain metastases.

Ajithkumar T, Parkinson C, Fife K, Corrie P, Jefferies S.

Lancet Oncol. 2015 Oct;16(13):e486-97. doi: 10.1016/S1470-2045(15)00141-2. Review.

PMID:
26433822
5.

Safety and Efficacy of Modified FOLFIRINOX for Advanced Pancreatic Adenocarcinoma: A UK Single-Centre Experience.

Ghorani E, Wong HH, Hewitt C, Calder J, Corrie P, Basu B.

Oncology. 2015;89(5):281-7. doi: 10.1159/000439171. Epub 2015 Sep 16.

PMID:
26372905
6.

Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients.

Ahmad SS, Qian W, Ellis S, Mason E, Khattak MA, Gupta A, Shaw H, Quinton A, Kovarikova J, Thillai K, Rao A, Board R, Nobes J, Dalgleish A, Grumett S, Maraveyas A, Danson S, Talbot T, Harries M, Marples M, Plummer R, Kumar S, Nathan P, Middleton MR, Larkin J, Lorigan P, Wheater M, Ottensmeier CH, Corrie PG.

Melanoma Res. 2015 Oct;25(5):432-42. doi: 10.1097/CMR.0000000000000185.

7.

Unmet clinical needs in the management of advanced melanoma: findings from a survey of oncologists.

Jones C, Clapton G, Zhao Z, Barber B, Saltman D, Corrie P.

Eur J Cancer Care (Engl). 2015 Nov;24(6):867-72. doi: 10.1111/ecc.12359. Epub 2015 Jul 29.

PMID:
26222136
8.

Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial.

Valle JW, Wasan H, Lopes A, Backen AC, Palmer DH, Morris K, Duggan M, Cunningham D, Anthoney DA, Corrie P, Madhusudan S, Maraveyas A, Ross PJ, Waters JS, Steward WP, Rees C, Beare S, Dive C, Bridgewater JA.

Lancet Oncol. 2015 Aug;16(8):967-78. doi: 10.1016/S1470-2045(15)00139-4. Epub 2015 Jul 12. Erratum in: Lancet Oncol. 2015 Sep;16(9):e427.

9.

Seasonal variation in diagnosis of invasive cutaneous melanoma in Eastern England and Scotland.

Walter FM, Abel GA, Lyratzopoulos G, Melia J, Greenberg D, Brewster DH, Butler H, Corrie PG, Campbell C.

Cancer Epidemiol. 2015 Aug;39(4):554-61. doi: 10.1016/j.canep.2015.06.006. Epub 2015 Jul 2.

10.

Treatment patterns in advanced melanoma: findings from a survey of European oncologists.

Jones C, Zhao Z, Barber B, Bagijn M, Corrie P, Saltman D.

Eur J Cancer Care (Engl). 2015 Nov;24(6):862-6. doi: 10.1111/ecc.12326. Epub 2015 May 18.

PMID:
25988349
11.

Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma.

Welsh SJ, Corrie PG.

Ther Adv Med Oncol. 2015 Mar;7(2):122-36. doi: 10.1177/1758834014566428. Review.

12.

Salvage pancreaticoduodenectomy after complete response to chemoradiotherapy for a previously unresectable pancreatic adenosquamous carcinoma: a case report.

Elias A, Chatzizacharias NA, Xanthis A, Corrie P, Davies S, Brais RJ, Jamieson NV, Praseedom RK, Huguet E, Harper SJ, Jah A.

Medicine (Baltimore). 2015 Feb;94(6):e499. doi: 10.1097/MD.0000000000000499.

13.

Endothelin-1 and endothelin B receptor expression in pancreatic adenocarcinoma.

Cook N, Brais R, Qian W, Hak CC, Corrie PG.

J Clin Pathol. 2015 Apr;68(4):309-13. doi: 10.1136/jclinpath-2014-202521. Epub 2015 Jan 8.

PMID:
25572612
14.

PACMEL: a phase 1 dose escalation trial of trametinib (GSK1120212) in combination with paclitaxel.

Coupe N, Corrie P, Hategan M, Larkin J, Gore M, Gupta A, Wise A, Suter S, Ciria C, Love S, Collins L, Middleton MR.

Eur J Cancer. 2015 Feb;51(3):359-66. doi: 10.1016/j.ejca.2014.11.018. Epub 2014 Dec 24.

PMID:
25542057
15.

Pyogenic granuloma as a cutaneous adverse effect of vemurafenib.

Sammut SJ, Tomson N, Corrie P.

N Engl J Med. 2014 Sep 25;371(13):1265-7. doi: 10.1056/NEJMc1407683. No abstract available.

16.

Management of melanoma.

Corrie P, Hategan M, Fife K, Parkinson C.

Br Med Bull. 2014 Sep;111(1):149-62. doi: 10.1093/bmb/ldu019. Review.

PMID:
25190764
17.

Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial.

Middleton G, Silcocks P, Cox T, Valle J, Wadsley J, Propper D, Coxon F, Ross P, Madhusudan S, Roques T, Cunningham D, Falk S, Wadd N, Harrison M, Corrie P, Iveson T, Robinson A, McAdam K, Eatock M, Evans J, Archer C, Hickish T, Garcia-Alonso A, Nicolson M, Steward W, Anthoney A, Greenhalf W, Shaw V, Costello E, Naisbitt D, Rawcliffe C, Nanson G, Neoptolemos J.

Lancet Oncol. 2014 Jul;15(8):829-40. doi: 10.1016/S1470-2045(14)70236-0. Epub 2014 Jun 19.

PMID:
24954781
18.

Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study.

Corrie PG, Marshall A, Dunn JA, Middleton MR, Nathan PD, Gore M, Davidson N, Nicholson S, Kelly CG, Marples M, Danson SJ, Marshall E, Houston SJ, Board RE, Waterston AM, Nobes JP, Harries M, Kumar S, Young G, Lorigan P.

Lancet Oncol. 2014 May;15(6):620-30. doi: 10.1016/S1470-2045(14)70110-X. Epub 2014 Apr 15. Erratum in: Lancet Oncol. 2014 Aug;15(9):e365. Lancet Oncol. 2014 Jun;15(7):e253.

19.

"It can't be very important because it comes and goes"--patients' accounts of intermittent symptoms preceding a pancreatic cancer diagnosis: a qualitative study.

Evans J, Chapple A, Salisbury H, Corrie P, Ziebland S.

BMJ Open. 2014 Feb 18;4(2):e004215. doi: 10.1136/bmjopen-2013-004215.

20.

Capecitabine and streptozocin ± cisplatin in advanced gastroenteropancreatic neuroendocrine tumours.

Meyer T, Qian W, Caplin ME, Armstrong G, Lao-Sirieix SH, Hardy R, Valle JW, Talbot DC, Cunningham D, Reed N, Shaw A, Navalkissoor S, Luong TV, Corrie PG.

Eur J Cancer. 2014 Mar;50(5):902-11. doi: 10.1016/j.ejca.2013.12.011. Epub 2014 Jan 17.

PMID:
24445147
Items per page

Supplemental Content

Loading ...
Write to the Help Desk